e-learning
resources
Vienna 2009
Monday, 14.09.2009
Treatment and prevention of lower respiratory tract infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antioxidant defence at the beginning of community-acquired pneumonia with lung infiltrative affection of different duration
T. Zhavoronok, E. Stepovaya, N. Ryazanceva, F. Tetenev, T. Ageeva, S. Mishustin (Tomsk, Russian Federation)
Source:
Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Session:
Treatment and prevention of lower respiratory tract infections
Session type:
Thematic Poster Session
Number:
2420
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Zhavoronok, E. Stepovaya, N. Ryazanceva, F. Tetenev, T. Ageeva, S. Mishustin (Tomsk, Russian Federation). Antioxidant defence at the beginning of community-acquired pneumonia with lung infiltrative affection of different duration. Eur Respir J 2009; 34: Suppl. 53, 2420
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Estimation of inflammatory process activity in community-acquired pneumonia
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Difference of immune response in patients with severe acute pneumonia and lung abscesses
Source: Eur Respir J 2004; 24: Suppl. 48, 189s
Year: 2004
Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
The post-tuberculosis lung changes as risk factor of the community-acquired pneumonia delayed course
Source: Eur Respir J 2006; 28: Suppl. 50, 351s
Year: 2006
The tobacco-smoking influence on the community-acquired pneumonia course
Source: Eur Respir J 2006; 28: Suppl. 50, 247s
Year: 2006
Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections
Source: Eur Respir Monogr 2020; 88: 212-228
Year: 2020
Effects of systemic steroids in patients with severe community-acquired pneumonia
Source: Eur Respir J 2007; 30: 951-956
Year: 2007
Inflammatory pattern in bacteriemic community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Adrenal function is related to prognosis in moderate community-acquired pneumonia
Source: Eur Respir J 2010; 36: 615-621
Year: 2010
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Evolution of antimicrobial susceptibility of respiratory isolates in chronic obstructive pulmonary patients diagnosed of acquired community pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Evaluation of incidental exacerbation of interstitial pneumonia in patients with non-respiratory diseases
Source: International Congress 2017 – Rare diseases
Year: 2017
Treatment of suppurative lung disease
Source: ISSN=1025-448x, ISBN=1-904097-33-2, page=168
Year: 2004
Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003
The possibility to predict the danger of destabilization development of the ischemic heart disease course in patients with community-acquired pneumonia infected with chlamydophila pneumonia
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010
Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with
Pneumocystis
pneumonia
Source: ERJ Open Res, 6 (2) 00306-2019; 10.1183/23120541.00306-2019
Year: 2020
Pulmonary tuberculosis in the differential diagnosis of community-acquired pneumonia
Source: Eur Respir J 2012; 40: 279
Year: 2012
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept